Clinical trials: High-Risk Localized Prostate Cancer

Prostate Cancer

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

• Completed
• Age: All ages
• Phase 2
• Results posted

Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1.

Trial name

NCT00500110

Testing

Docetaxel, Imatinib Mesylate, Leuprolide

Where

United States

Volunteers

39 people

Sponsor

M.D. Anderson Cancer Center